GlassScriptPhysician profile
Randall S Martz
NPI 1972598456
$1,776.09
in general payments reported to CMS, 2019-2025
27 companies · $67.85 in 2025
The $67.85 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.51 · 2022: $316 · 2023: $800 · 2024: $535 · 2025: $67.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $300.67 | 2021-2024 | Jardiance, Zepbound, Emgality |
| Abbvie INC. | $267.40 | 2022-2024 | |
| Amgen INC. | $200.61 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $136.89 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $110.63 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $106.29 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $87.35 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $77.45 | 2022-2024 | Wegovy |
| Antares Pharma, INC. | $49.38 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $48.17 | 2023 | Trintellix |
| Pfizer INC. | $46.18 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.55 | 2022 | |
| Medtronic, INC. | $39.39 | 2025 | Inceptiv, Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $30.39 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $27.21 | 2024 | Spravato |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $21.37 | 2023 | Gralise, Loreev Xr |
| Axsome Therapeutics, INC. | $20.74 | 2024 | Auvelity |
| Corium, LLC | $19.42 | 2022 | |
| Seqirus USA INC | $19.27 | 2022 | |
| Kaleo, INC. | $16.91 | 2022 | |
| Impel Pharmaceuticals INC. | $16.49 | 2023 | Trudhesa |
| Amarin Pharma, INC. | $16.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.69 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.95 | 2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.88 | 2024 | Jardiance |
| Therapeuticsmd, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Martz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.